Clinical trials: Cytarabine, completed
Acute Myeloid Leukemia
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3)…
- Trial name
- NCT03379727
- Testing
- Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only
- Where
- 86 sites in Bulgaria, Croatia and 13 more
- Volunteers
- 301 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloblastic Leukemia
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
Second-line induction therapy with fludarabine, idarubicin, cytarabine,Granulocyte colony-stimulating factor (G-CSF) and plerixafor, in patients with relapsed or refractory Acute Myeloblastic Leukemia (AML) aged 65 or younger.
- Trial name
- NCT01435343
- Testing
- fludarabine, Idarubicin, cytarabine
- Where
- 10 sites in Spain
- Volunteers
- 55 people
- Sponsor
- PETHEMA Foundation
Philadelphia Positive Acute Lymphoblastic Leukemia
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
The current standard treatment approach for young patients with Positive Acute Lymphoblastic Leukemia (Ph+ALL) is the combination of a chemotherapy protocol employing four to five cytotoxic agents typically used for ALL together…
- Trial name
- NCT01724879
- Testing
- Dasatinib
- Where
- 22 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Goethe University
Non-Hodgkin Lymphoma, Hodgkin Disease
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts.
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia
- Trial name
- NCT00039910
- Testing
- (PN-152,243)/ PN-196,444
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 240 people
- Sponsor
- Pfizer
Lymphoma
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238368
- Testing
- filgrastim, rituximab, busulfan
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003671
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 59 people
- Sponsor
- Children's Oncology Group
Acute Leukemia, Relapsed, Acute Leukemia Refractory
CAV Regimen Bridging to HSCT for R/R AL
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for acute leukemia (AL), relapsed or refractory (R/R) AL is still a big challenge.
- Trial name
- NCT05190549
- Testing
- CAV regimen bridging to HSCT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03813147
- Testing
- Azacitidine, Cytarabine, Fludarabine Phosphate
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute…
- Trial name
- NCT04620681
- Testing
- CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia
High-dose Cytarabine and Survival in AML
In adults with acute myeloid leukemia, especially those < 60 years of age, high-dose cytarabine consolidation therapy has been shown to influence survival, but the appropriate dose has not been defined.
- Trial name
- NCT01034839
- Where
- Brazil
- Volunteers
- 499 people
- Sponsor
- University of Sao Paulo General Hospital
Leukemia, Lymphocytic, Lymphoblastic Lymphoma
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL).
- Conditions
- Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia
- Trial name
- NCT03792256
- Testing
- Palbociclib, Cytarabine, Methotrexate
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Oncology Group
Newly Diagnosed Secondary or High Risk AML
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
This protocol corresponds to a prospective, multicentre, open label, phase II study designed to evaluate the efficacy of CPX-351 in elderly patients with secondary or high-risk AML.
- Trial name
- LAMVYX (NCT04230239)
- Testing
- CPX-351
- Where
- 12 sites in Spain
- Volunteers
- 59 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The primary purpose of the study is to determine, whether the addition of 5-azacytidine to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
- Trial name
- AML-AZA (NCT00915252)
- Testing
- azacitidine, standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
- Where
- 27 sites in Germany
- Volunteers
- 214 people
- Sponsor
- University Hospital Muenster
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia, Pediatric
Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia
The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive…
- Trial name
- NCT03165851
- Testing
- Risk-stratified therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myelogenous Leukemia
Alisertib for Acute Myeloid Leukemia
This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs.
- Trial name
- NCT01779843
- Testing
- Cytarabine, Idarubicin, Alisertib
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Posttransplant Lymphoproliferative Disorder
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Post-transplant lymphoproliferative disorders (PTLD) differ clinically from lymphoma in the general (immunocompetent) population due to their higher incidence and their frequent association with Epstein-Barr virus.
- Trial name
- PTLD-2 (NCT02042391)
- Testing
- Rituximab sc, Rituximab sc consolidation, Rituximab sc combined with CHOP chemotherapy
- Where
- 18 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Lymphoma, Non-Hodgkin, HIV Infections
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL.
- Trial name
- NCT00000658
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Waldenström Macroglobulinemia
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
The purpose of this study is to evaluate whether autologous stem cell transplantation will improve the survival of patients with high-risk Waldenström macroglobulinemia, compared with conventional chemotherapy.
- Trial name
- BDH-WM03 (NCT02844361)
- Testing
- autologous stem cell transplantation, conventional chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, AML
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety and tolerability of Palbociclib in combination with investigational (experimental) drug, CPX-351 and evaluate the efficacy of Palbociclib in combination with chemotherapy as…
- Trial name
- NCT03844997
- Testing
- Palcociclib, CPX-351
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sudipto Mukherjee, MD, PhD, MPH